Breadcrumb
- Home /
- Research /
- Researcher Profiles /
- Researchers /
- Jonathan Spicer, B.Sc. (Hon), MD, PhD, FRCS
null Jonathan Spicer, B.Sc. (Hon), MD, PhD, FRCS
Scientist, RI-MUHC
Cancer Research ProgramCentre for Translational Biology
Professor, Department of Surgery, Faculty of Medicine and Health Sciences, McGill University
Department of Surgery, Division of Adult Thoracic Surgery, MUHC
Keywords
lung cancer • neoadjuvant • immunotherapy • neutrophil • surgery
Research Focus
My research focuses on the continuum of care for patients with lung cancer. Our lab studies the interplay between the innate and adaptive immune system during lung cancer progression and in response to conventional and novel therapeutics. In particular, our lab has expertise in the biology of neutrophil extracellular traps during cancer progression and in response to therapy. From clinical and translational perspectives, I lead one of the world's most active programs in neoadjuvant therapy for patients with operable lung cancer and leverage this clinical activity for correlative science designed to understand metrics of response and failure to emerging treatments.
Selected Publications
Click on
to see my current publications list
-
Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, Felip E, Broderick SR, Brahmer J, Swanson SJ, Kerr K, Wang C, Ciuleanu TE, Saylors GB, Tanaka F, Ito H, Chen KN, Liberman M, Vokes EE, Taube JM, Dorange C, Cai J, Fiore J, Jarkowski A, Balli D, Sausen M, Pandya D, Calvet C, Girard N. Neoadjuvant Nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med. 2022 May 26;386(21):1973-1985. DOI: 10.1056/NEJMoa2202170. PMID: 35403841.
-
Cools-Lartigue J*, Spicer J*, McDonald B, Gowing S, Chow S, Giannias B, Bourdeau F, Kubes P, Ferri L. Neutrophil extracellular traps sequester circulating tumor cells and promote metastasis. J Clin Invest. 2013 Jul 1;123(8):3446–58. doi: 10.1172/JCI67484. Epub ahead of print. PMID: 23863628.
-
Sorin M, Rezanejad M, Karimi E, Fiset B, Desharnais L, Perus LJM, Milette S, Yu MW, Maritan SM, Doré S, Pichette É, Enlow W, Gagné A, Wei Y, Orain M, Manem VSK, Rayes R, Siegel PM, Camilleri-Broët S, Fiset PO, Desmeules P, Spicer JD, Quail DF, Joubert P, Walsh LA. Single-cell spatial landscapes of the lung tumour immune microenvironment. Nature. 2023 Feb;614(7948):548-554. doi: 10.1038/s41586-022-05672-3. Epub 2023 Feb 1. PMID: 36725934.
-
Sorin M, Prosty C, Ghaleb L, Nie K, Katergi K, Shahzad MH, Dubé LR, Atallah A, Swaby A, Dankner M, Crump T, Walsh LA, Fiset PO, Sepesi B, Forde PM, Cascone T, Provencio M, Spicer JD. Neoadjuvant Chemoimmunotherapy for NSCLC: A Systematic Review and Meta-Analysis. JAMA Oncol. 2024 May 1;10(5):621-633. doi: 10.1001/jamaoncol.2024.0057. PMID: 38512301.
-
Spicer JD, Garassino MC, Wakelee H, Liberman M, Kato T, Tsuboi M, Lee SH, Chen KN, Dooms C, Majem M, Eigendorff E, Martinengo GL, Bylicki O, Rodríguez-Abreu D, Chaft JE, Novello S, Yang J, Arunachalam A, Keller SM, Samkari A, Gao S; KEYNOTE-671 Investigators. Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2024 Sep 28;404(10459):1240-1252. doi: 10.1016/S0140-6736(24)01756-2. Epub 2024 Sep 14. PMID: 39288781.